TY - JOUR AU - Van Brussel, Ilse AU - Van Craenenbroeck, Amaryllis H. AU - Schrijvers, Dorien M. AU - Cools, Nathalie PY - 2012 TI - Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives? JF - Translational Andrology and Urology; Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology Y2 - 2012 KW - N2 - Renal cell carcinoma (RCC) constitutes 80 to 85 percent of primary renal neoplasms in adults (1). Although surgical resection can be curative in localized disease, many patients eventually recur. Patients with locally advanced or metastatic disease have a poor prognosis, with a 5-year survival rate of less than 15%. UR - https://tau.amegroups.org/article/view/1138